NCT02362997 · OUTCOME

Relapse

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Number of patients who relapse within 18 months from autologous stem cell transplantation.

Analysis population: Patients who have been followed for at least 18 months or have relapsed prior to 18 months post ASCT

Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Diffuse Large B Cell Lymphoma	25
Classical Hodgkin Lymphoma	28
Peripheral T Cell Lymphoma	16

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Diffuse Large B Cell Lymphoma	11	Not reported	Not reported	Not reported	Not reported
Classical Hodgkin Lymphoma	4	Not reported	Not reported	Not reported	Not reported
Peripheral T Cell Lymphoma	4	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Number of patients who relapse within 18 months from autologous stem cell transplantation.

groups

param Type

COUNT_OF_PARTICIPANTS

population Description

Patients who have been followed for at least 18 months or have relapsed prior to 18 months post ASCT

reporting Status

POSTED

time Frame

18 Months

title

Relapse

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice